nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

05.07.2016 | Original Article – Clinical Oncology

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB

verfasst von: Jizhuang Luo, Qingyuan Huang, Rui Wang, Baohui Han, Jie Zhang, Heng Zhao, Wentao Fang, Qingquan Luo, Jun Yang, Yunhai Yang, Lei Zhu, Tianxiang Chen, Xinghua Cheng, Yiyang Wang, Jiajie Zheng, Han Wu, Weicong Xia, Haiquan Chen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Controversy remains exist for the effect of adjuvant chemotherapy (ACT) among stage IB lung adenocarcinoma patients. This study aimed to investigate the predictive value of the current lung adenocarcinoma classification system on benefit of ACT among patients with stage IB lung adenocarcinoma.

Methods

A total of 928 pathological stage IB invasive adenocarcinoma patients with R0 resection were included in this study. Based on the predominant growth pattern present in the tumor, invasive adenocarcinomas with mixed histologic components were classified into five subtypes: lepidic (LEP), acinar (ACN), papillary (PAP), micropapillary (MIP) and solid (SOL). These five histologic subtypes were collapsed into three groups (LEP, ACN/PAP and SOL/MIP). Disease-free survival (DFS) and overall survival (OS) were analyzed to evaluate benefit from ACT in patients with different histologic patterns using the Kaplan–Meier approach and multivariable Cox models.

Results

For all stage IB invasive adenocarcinoma patients, SOL/MIP subgroup presented the worst prognosis, and LEP subgroup showed approximately 100 % 5-year survival. ACT was associated with a better DFS (HR, 0.70; 95 % CI 0.51–0.96, p = .026) for all stage IB patients. In SOL/MIP subgroup, patients could benefit from ACT for a significant improved DFS (HR, 0.81; 95 % CI 0.49–1.35; p = .030), but not for OS (HR, 0.39; 95 % CI 0.12–1.30, p = .111). In ACN/PAP subgroup, there was no significant benefit from ACT for both DFS (HR, 0.76; 95 % CI 0.54–1.08, p = .125) and OS (HR, 0.81; 95 % CI 0.49–1.35, p = .421).

Conclusions

SOL/MIP predominant pattern was predictive for ACT benefit for DFS among invasive lung adenocarcinoma patients in stage IB.

Bueno R et al (2015) Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 10:67–73. doi:10.1097/JTO.0000000000000365 CrossRefPubMed

Campos-Parra AD, Aviles A, Contreras-Reyes S, Rojas-Marin CE, Sanchez-Reyes R, Borbolla-Escoboza RJ, Arrieta O (2014) Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. The European Respiratory Journal 43:1439–1447. doi:10.1183/09031936.00138813 CrossRefPubMed

Coutinho D, Goncalves A, Antunes A, Campainha S, Miranda J, Barroso A (2016) Adjuvant chemotherapy in stage IB non-small cell lung carcinoma: a survival analysis. Revista portuguesa de pneumologia 22:123–125. doi:10.1016/j.rppnen.2015.09.005 CrossRefPubMed

Donington JS (2016) An additional step toward personalization of surgical care for early-stage non-small-cell lung cancer. J Clin Oncol 34:295–296. doi:10.1200/JCO.2015.64.7578 CrossRefPubMed

Ettinger DS et al (2015) Non-small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw JNCCN 13:515–524PubMed

Friboulet L et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. New Engl J Med 368:1101–1110. doi:10.1056/NEJMoa1214271 CrossRefPubMedPubMedCentral

Goldstraw P et al (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706–714. doi:10.1097/JTO.0b013e31812f3c1a CrossRefPubMed

Goldstraw P et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51. doi:10.1016/j.jtho.2015.09.009 CrossRefPubMed

Huang Q et al (2016) Identification and validation of lymphovascular invasion as a prognostic and staging factor in node-negative esophageal squamous cell carcinoma. J Thorac Oncol 11:583–592. doi:10.1016/j.jtho.2015.12.109 CrossRefPubMed

Hung JJ, Jeng WJ, Chou TY, Hsu WH, Wu KJ, Huang BS, Wu YC (2013) Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 258:1079–1086. doi:10.1097/SLA.0b013e31828920c0 CrossRefPubMed

Li Z et al (2009) Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J Thorac Oncol 4:702–709. doi:10.1097/JTO.0b013e3181a5269d CrossRefPubMed

Park SY et al (2013) Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg 8:151. doi:10.1186/1749-8090-8-151 CrossRefPubMedPubMedCentral

Pignon JP et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552–3559. doi:10.1200/JCO.2007.13.9030 CrossRefPubMed

Pirker R (2014) Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. Transl Lung Cancer Res 3:305–310. doi:10.3978/j.issn.2218-6751.2014.09.13 PubMedPubMedCentral

Russell PA, Wright GM (2016) Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail? Ann Transl Med 4:16. doi:10.3978/j.issn.2305-5839.2015.10.21 PubMedPubMedCentral

Shim HS et al (2015) Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol 10:1156–1162. doi:10.1097/JTO.0000000000000579 CrossRefPubMed

Takahashi Y, Eguchi T, Bains S, Adusumilli PS (2016) Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy. Ann Transl Med 4:66. doi:10.3978/j.issn.2305-5839.2015.10.40 PubMedPubMedCentral

Travis WD et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285. doi:10.1097/JTO.0b013e318206a221 CrossRefPubMedPubMedCentral

Tsao MS et al (2015) Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 33:3439–3446. doi:10.1200/JCO.2014.58.8335 CrossRefPubMed

Warth A et al (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446. doi:10.1200/JCO.2011.37.2185 CrossRefPubMed

Wilcox JE (2006) DNA repair by ERCC1 in non-small-cell lung cancer. New Engl J Med 355:2590 (author reply 2591) CrossRefPubMed

Xu CH et al (2015) Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma. Eur J Surg Oncol 41:1430–1436. doi:10.1016/j.ejso.2015.06.004 CrossRefPubMed

Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G (2013) New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 8:612–618. doi:10.1097/JTO.0b013e318287c3eb CrossRefPubMed

Yoshida T et al (2013) Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol 139:1691–1700. doi:10.1007/s00432-013-1495-0 CrossRefPubMed

Yoshizawa A et al (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24:653–664. doi:10.1038/modpathol.2010.232 CrossRefPubMed

Yoshizawa A et al (2013) Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8:52–61. doi:10.1097/JTO.0b013e3182769aa8 CrossRefPubMed

Zhang J, Wu J, Tan Q, Zhu L, Gao W (2013) Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol 8:1196–1202. doi:10.1097/JTO.0b013e31829f09a7 CrossRefPubMed

Zhang Y et al (2014) The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep 4:7163. doi:10.1038/srep07163 CrossRefPubMedPubMedCentral

Zhu ZH et al (2009) Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 27:1091–1099. doi:10.1200/JCO.2008.16.6991 CrossRefPubMed

Titel: Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB
verfasst von: Jizhuang Luo
Qingyuan Huang
Rui Wang
Baohui Han
Jie Zhang
Heng Zhao
Wentao Fang
Qingquan Luo
Jun Yang
Yunhai Yang
Lei Zhu
Tianxiang Chen
Xinghua Cheng
Yiyang Wang
Jiajie Zheng
Han Wu
Weicong Xia
Haiquan Chen
Publikationsdatum: 05.07.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2192-6

Springer Medizin

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB